Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Abgenix, Inc. (ABGX) -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (312)	2/3/2004 8:17:44 AM
From: nigel bates	Respond to of 590

what Abgenix think that they are doing... No more than this ? "...It also meets our goal to advance one non-oncology product candidate into the clinic this year..."

To: Icebrg who wrote (312)	2/4/2004 5:32:29 PM
From: Icebrg	Read Replies (1) \| Respond to of 590

>>It would really be interesting to hear what Abgenix think that they are doing.>> Withy talked a little about this at the Merril Lynch presentation. The main potential advantages might be: - The drug "will" have a direct dose-dependent impact on the PTH-levels. The mAb binds directly to PTH, while alternative drugs (like for example NPSP/Amgen's Cinacalcet) works indirectly. - Abgenix expects their drug to have a long(er) half-life making it possible to tailor administration of the drug to the dialyses these patients are receiving. Erik